【北京，中国】人工智能个性化手术医疗科技公司 Carlsmed 近日宣布成功完成了一轮5250万美元的C轮融资，此轮融资由知名投资机构B Capital和US Venture Partners共同领投。这标志着Carlsmed在医疗科技领域的创新再次获得业界的高度认可和资金支持。
Carlsmed致力于利用人工智能技术为患者提供定制化的手术解决方案。本次筹集的资金将主要用于aprevo ®个性化脊柱手术平台的商业化进程，该平台在腰椎融合手术中已经展现出显著的临床效果。此外，公司还将加速开发适用于颈椎融合手术的新版aprevo ®平台，预计将于2025年正式推出，为更多患者带来精准且高效的治疗选择。
Carlsmed的这一轮融资不仅将推动其核心技术的进一步发展，也将助力公司在全球范围内扩大市场影响力，让更多医疗机构和患者受益于其创新的手术技术。此次B Capital和US Venture Partners的联合投资，无疑为Carlsmed在人工智能医疗领域的探索提供了坚实的后盾，预示着公司在未来将有更大的发展空间。
Carlsmed的首席执行官表示：“我们非常感谢投资者的信任和支持，这笔资金将加速我们为患者提供更个性化、更安全的手术服务的进程。我们期待aprevo ®平台在颈椎手术领域的应用能够为医疗行业带来革命性的变化。”
此次融资事件再次凸显了人工智能在医疗健康领域的巨大潜力，尤其是对于提高手术精准度和患者康复效果方面的显著作用。Carlsmed的成功故事将鼓励更多的科技公司投身于医疗科技的研发，以期在这一快速发展的领域中创造更多价值。
英语如下：
**News Title:** “Carlsmed Raises $52.5 Million in Series C Funding to Accelerate AI-Powered Personalized Spine Surgery Platform”
**Keywords:**
**News Content:**
**[Beijing, China]** Carlsmed, a pioneering AI-driven personalized surgical technology company, recently announced the successful completion of a $52.5 million Series C funding round, co-led by prominent investors B Capital and US Venture Partners. This financing signals continued industry recognition and support for Carlsmed’s innovations in the medical technology sector.
Carlsmed is dedicated to leveraging artificial intelligence to offer tailored surgical solutions to patients. The funds raised will predominantly fuel the commercialization of the aprevo ® personalized spine surgery platform, which has demonstrated substantial clinical benefits in lumbar fusion surgeries. Additionally, the company aims to accelerate the development of an updated aprevo ® platform for cervical fusion procedures, expected to launch in 2025, offering more patients precise and efficient treatment options.
This latest funding round will not only propel the advancement of Carlsmed’s core technology but also facilitate the expansion of its global market presence, enabling more healthcare institutions and patients to benefit from its innovative surgical techniques. The joint investment from B Capital and US Venture Partners solidifies Carlsmed’s foundation in the AI healthcare landscape, forecasting substantial growth potential for the company in the future.
Commenting on the funding, the CEO of Carlsmed said, “We are immensely grateful for the trust and support from our investors. This capital will expedite our efforts to provide more personalized and safer surgical services to patients. We look forward to the revolutionary impact the aprevo ® platform will have on cervical surgeries in the healthcare industry.”
This financing underscores the immense potential of artificial intelligence in the healthcare sector, particularly in enhancing surgical precision and patient recovery outcomes. Carlsmed’s success story is expected to inspire more technology companies to invest in medical technology research and development, contributing further value in this rapidly evolving field.
【来源】https://www.businesswire.com/news/home/20240318820510/en/Carlsmed-Raises-52.5M-in-Series-C-Financing-to-Advance-Personalized-Spine-Surgery
Views: 1